Fourth Friday at Four: Zomedica Clinical Studies Deep Dive - ZOMEDICA CORP

Financial Performance:

• Zomedica aims to achieve cash flow positivity in the fourth quarter of the current year and adjusted EBITDA positivity in 2027, driven by revenue growth and controlled expenses.
• Consumables represent approximately 70% of total company revenue; the Truforma platform generates 100% recurring revenue from cartridge sales as analyzers are placed at no charge.
• Truforma revenue has grown nearly 100% year-over-year, with significant acceleration in the equine segment due to new assays and the partnership with Boehringer Ingelheim.
• R&D expenses have decreased from 2025 levels, with further reductions expected in 2027 as current development projects are completed and ready for launch.
• The company maintains a strong balance sheet and intends to retain capital for growth rather than pursue stock buybacks until cash flow positivity is sustained.

Guidance and Future Outlook:

• Management expects to reach adjusted EBITDA positivity in 2027 through a combination of continued revenue growth (particularly in consumables) and reduced operating expenses from prior restructuring.
• New product launches scheduled for late 2026 and early 2027 (including three equine assays at the AAEP meeting) are projected to contribute significantly to 2027 revenue growth.
• The company plans to accelerate growth in 2027 by targeting large veterinary hospital chains (e.g., VMG, NVA, VetCorps) with integrated programs for Truforma and PIMS.
• Long-term strategy focuses on "land, deepen, and expand" clinical evidence to drive device adoption, increase usage frequency, and introduce new products into existing accounts.

Business Segments and Product Lines:

• PulseVet Shockwave: Recent studies demonstrate efficacy in treating equine asthma (improving owner ratings by 69% and cough reduction in 90% of horses), stimulating hoof growth in horses, and accelerating bone healing post-TPLO surgery in dogs.
• VetGuardian Plus: A touchless, radar-based vital sign monitor validated against wearable collars, showing strong agreement for heart and respiratory rates; designed to improve clinic workflow and reduce patient stress.
• Truforma Immunoassay: A point-of-care platform validated for feline hyperthyroidism (superior sensitivity to T4) and equine PPID/insulin dysregulation (strong correlation with reference labs); expanding the test menu to drive recurring cartridge revenue.
• VetaGel & Assisi Loop: VetaGel is a surgical hemostatic agent used for rapid bleeding control in various procedures; the Assisi Loop is a low-intensity electrical stimulation device for pain management and mobility recovery.

Market and Competitive Landscape:

• Zomedica differentiates itself by prioritizing clinical evidence published in peer-reviewed journals, contrasting with competitors that often lack robust data behind their veterinary products.
• The company is actively expanding into the equine market with Truforma, leveraging existing relationships with PulseVet customers and strategic partnerships with organizations like Boehringer Ingelheim.
• Key opinion leaders (KOLs) and independent university studies are utilized to validate products, build trust, and influence peer-to-peer adoption among veterinarians.
• The market for veterinary diagnostics and therapeutics is growing, with a specific demand for in-clinic testing that reduces wait times for results compared to reference laboratories.

Risks and Challenges:

• Regulatory hurdles for expanding into the human market (e.g., FDA clearance for sports injuries) are currently deemed too costly and outside the immediate strategic focus.
• The company must balance aggressive R&D investment for future growth with the strict timeline to achieve 2027 profitability and cash flow positivity.
• Stock price volatility is acknowledged, with management noting that institutional investor interest and capital structure are key factors influencing market valuation.
• Reliance on the veterinary ecosystem for evidence generation means adoption rates are tied to the willingness of practitioners to validate and integrate new technologies.

Management Commentary and Tone:

• CEO Larry Heaton and the management team maintain a confident and transparent tone, emphasizing that clinical evidence is the primary driver of adoption and recurring revenue.
• Management is proactive in addressing analyst concerns regarding capital structure, acquisitions, and future roadmap, while maintaining confidentiality on non-material competitive plans.
• The tone regarding 2027 is optimistic, asserting that the company is on a clear path to EBITDA positivity through operational discipline and strategic product rollouts.
• Management emphasizes the importance of "critical mass" in 2027, anticipating that the full product portfolio and PIMS integration will allow for significant inroads into large hospital chains.

Analyst Questions and Answers:

• Profitability: Confirmed plan for cash flow positivity in Q4 and adjusted EBITDA positivity in 2027; GAAP profitability is the ultimate long-term goal.
• Listings: Plans to uplist from OTC to NYSE are active but contingent on meeting share price requirements; the company is not pursuing a Canadian listing.
• Acquisitions: No undisclosed material acquisition talks; any future M&A would be subject to fair disclosure regulations.
• Human Market: FDA clearance for human use is not currently planned due to cost; the focus remains on the animal health sector.
• Equine Growth: The equine segment is identified as the fastest-growing area for Truforma, with high adoption rates in a smaller addressable market of ~2,400 accounts.
• Payback Period: The time to recover analyzer costs is improving as higher-volume assays are added to the Truforma platform.

Other Key Points:

• Zomedica has implemented a "Fourth Friday at Four" webinar series to engage investors with clinical data and company updates.
• A new Upstream Product Manager role has been established to align research, sales, and clinical evidence to maximize product adoption.
• The company is leveraging digital marketing (Meta, Facebook, LinkedIn) and influencer programs rather than traditional print advertising to generate leads.
• PIMS integration for existing and new products is scheduled for full launch at the AAEP meeting in December.
• Management intends to continue hiring corporate account executives to target large veterinary groups, similar to successful strategies employed by Antech.